A Novel First-Line Treatment Alternative for Noncomplicated Idiopathic Granulomatous Mastitis: Combined Intralesional Steroid Injection With Topical Steroid Administration

dc.contributor.author Toktaş, Osman
dc.contributor.author Konca, Can
dc.contributor.author Trabulus, Didem Can
dc.contributor.author Soyder, Aykut
dc.contributor.author Köksal, Hande
dc.contributor.author Karanlık, Hasan
dc.contributor.author Kamalı Polat, Ayfer
dc.contributor.author Özbaş, Serdar Mustafa
dc.contributor.author Yormaz, Serdar
dc.contributor.author Sezgin, Efe
dc.contributor.author Soran, Atilla
dc.coverage.doi 10.1159/000507951
dc.date.accessioned 2021-01-24T18:33:11Z
dc.date.available 2021-01-24T18:33:11Z
dc.date.issued 2021
dc.description.abstract Background: Idiopathic granulomatous mastitis (IGM) is a rare form of nonlactational mastitis. Due to the small number of case series and consequently inadequate prospective studies, there is still no consensus on the optimal treatment of IGM. In this study, we aimed to compare the efficacy of intralesional steroid injection with concomitant topical steroids to systemic steroid therapy only in the treatment of noncomplicated IGM. Methods: Between June 2015 and April 2018, the patients' data was prospectively collected and analyzed retrospectively. The study included a total of 78 female patients diagnosed with IGM. Patients were divided into 2 groups: the local steroid treatment group (intralesional steroid injection with topical steroid administration; group 1, n = 46) and the peroral systemic steroid treatment group (group 2, n = 32). Response to the therapy, side effects, recurrence, the need for surgical treatment, and complication rates were compared. Results: Forty-three patients (93.5%) in group 1 achieved a partial or complete response compared to 23 patients (71.9%) in group 2 after 3 months; this difference was significant (p = 0.012). The recurrence rates were significantly lower in group 1 (8.7%) compared to group 2 (46.9%; p = 0.001), and the need for surgical treatment was significantly less in group 1 (2.2%) than in group 2 (9.4%; p = 0.001). While the complication rates were similar between groups, a higher rate of systemic side effects was observed in group 2. Conclusion: Based on the results of our study, combined steroid injection and topical steroid treatment in IGM is as effective as systemic steroid treatment. We suggest that this combination therapy of topical steroids and local steroid injection should be used as first-line therapy in patients with noncomplicated IGM. © 2020 S. Karger AG, Basel. Copyright: All rights reserved. en_US
dc.identifier.doi 10.1159/000507951
dc.identifier.issn 1661-3791
dc.identifier.issn 1661-3805
dc.identifier.scopus 2-s2.0-85087911889
dc.identifier.uri https://doi.org/10.1159/000507951
dc.identifier.uri https://hdl.handle.net/11147/10238
dc.language.iso en en_US
dc.publisher S. Karger AG en_US
dc.relation.ispartof Breast Care en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Idiopathic granulomatous mastitis (IGM) en_US
dc.subject Non-complicated IGM en_US
dc.subject Steroid injection en_US
dc.subject Systemic steroid en_US
dc.subject Topical steroid en_US
dc.title A Novel First-Line Treatment Alternative for Noncomplicated Idiopathic Granulomatous Mastitis: Combined Intralesional Steroid Injection With Topical Steroid Administration en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.institutional Sezgin, Efe
gdc.bip.impulseclass C4
gdc.bip.influenceclass C4
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Institute of Technology. Food Engineering en_US
gdc.description.endpage 187
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q2
gdc.description.startpage 181
gdc.description.volume 16
gdc.description.wosquality Q2
gdc.identifier.openalex W3038982714
gdc.identifier.pmid 34012373
gdc.identifier.wos WOS:000642446100013
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype BRONZE
gdc.oaire.diamondjournal false
gdc.oaire.impulse 20.0
gdc.oaire.influence 4.501211E-9
gdc.oaire.isgreen false
gdc.oaire.popularity 3.023137E-8
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration International
gdc.openalex.fwci 9.37692014
gdc.openalex.normalizedpercentile 0.98
gdc.openalex.toppercent TOP 10%
gdc.opencitations.count 30
gdc.plumx.crossrefcites 28
gdc.plumx.mendeley 27
gdc.plumx.pubmedcites 20
gdc.plumx.scopuscites 37
gdc.scopus.citedcount 37
gdc.wos.citedcount 37
relation.isAuthorOfPublication.latestForDiscovery 77721b7d-10bb-4a8e-8cd8-10a1088bfb1b
relation.isOrgUnitOfPublication.latestForDiscovery 9af2b05f-28ac-4019-8abe-a4dfe192da5e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Name:
507951.pdf
Size:
236.86 KB
Format:
Adobe Portable Document Format